Finance

Lists
Why is TNXP down 6,67%?
Dive Deeper
TNXP:NASDAQ
Tonix Pharmaceuticals Holding Corp
2,38 US$
-6,67%
(-0,17) 1D
2,39 US$
+0,22% (+0,0052)
After hours
Closed: 20 ნოე, 16:00:01 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TNXP...
Open
2,56 US$
High
2,63 US$
Low
2,30 US$
Mkt. cap
46,25 მლნ.
Avg. vol.
1,11 მლნ.
Volume
1,26 მლნ.
52-wk high
20,56 US$
52-wk low
2,30 US$
EPS
-12,23 US$
Beta
1,90
Shares outstanding
19,43 მლნ.
No. of employees
142
Open
2,56 US$
High
2,63 US$
Low
2,30 US$
Mkt. cap
46,25 მლნ.
Avg. vol.
1,11 მლნ.
Volume
1,26 მლნ.
52-wk high
20,56 US$
52-wk low
2,30 US$
EPS
-12,23 US$
Beta
1,90
Shares outstanding
19,43 მლნ.
No. of employees
142
News stories
From web sources and news partners
Profile
Tonix Pharmaceuticals is a pharmaceutical company based in Chatham, New Jersey that focuses on repurposed drugs for central nervous system conditions and as of 2020 was also pursuing a vaccine for COVID-19 and a biodefense project. Wikipedia
About Tonix Pharmaceuticals Holding Corp
CEOსეთ ლედერმანი
Employees142
Founded2007
HeadquartersBerkeley Heights, ნიუ-ჯერსი, ამერიკის შეერთებული შტატები
SectorHealth Care
Industry-
Analyst ratings
Based on 4 analysts giving stock ratings to TNXP in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for TNXP in the last 3 months.
Highest
Current 2,38 US$
40,00 US$ (+1 580,67%)
Average
23,50 US$ (+887,39%)
Lowest
14,00 US$ (+488,24%)
Analyst
Recommendation
Action
Price target
Projected
Date
James Molloy
Alliance Global Partners
Buy
Maintained
40,00 US$
+1 580,7%
11/09/2026
Gary Nachman
Canaccord Genuity
Buy
Reiterated
18,00 US$
+656,3%
11/10/2026
Tiago Fauth
Raymond James
Buy
Reiterated
14,00 US$
+488,2%
11/09/2026
Stacy Ku
TD Cowen
Buy
Maintained
22,00 US$
+824,4%
10/21/2026
Robert LeBoyer
Noble Financial
Buy
Reiterated
37,00 US$
+1 454,6%
03/16/2026
Last report
9 ნოე. 2026
Fiscal period
Q3 2026
-2,89 US$ / -2,24 US$
-29,02%miss
Revenue / Est. (USD)
17,23 მლნ. / 16,32 მლნ.
+5,62%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
დეკ. 2025
მარ. 2026
ივნ. 2026
სექ. 2026
Revenue
5,39 მლნ.
6,88 მლნ.
13,54 მლნ.
17,23 მლნ.
Cost of goods sold
1,06 მლნ.
1,58 მლნ.
703,00 ათ.
1,25 მლნ.
Cost of revenue
1,06 მლნ.
1,58 მლნ.
703,00 ათ.
1,25 მლნ.
Research and development expenses
16,94 მლნ.
18,21 მლნ.
19,42 მლნ.
25,82 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
35,68 მლნ.
28,62 მლნ.
35,96 მლნ.
45,59 მლნ.
Operating expense
52,62 მლნ.
46,84 მლნ.
55,38 მლნ.
71,41 მლნ.
Total operating expenses
53,68 მლნ.
48,42 მლნ.
56,08 მლნ.
72,67 მლნ.
Operating income
-48,29 მლნ.
-41,54 მლნ.
-42,54 მლნ.
-55,43 მლნ.
Other non operating income
32,00 ათ.
-3,00 ათ.
551,00 ათ.
741,00 ათ.
EBT including unusual items
-46,91 მლნ.
-40,19 მლნ.
-40,55 მლნ.
-53,33 მლნ.
EBT excluding unusual items
-46,91 მლნ.
-40,19 მლნ.
-40,55 მლნ.
-53,33 მლნ.
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-46,91 მლნ.
-40,19 მლნ.
-40,55 მლნ.
-53,33 მლნ.
Net profit margin
-870,32%
-584,38%
-299,41%
-309,44%
Earnings per share
-3,98
-2,93
-2,47
-2,89
Interest and investment income
1,34 მლნ.
1,35 მლნ.
1,43 მლნ.
1,36 მლნ.
Interest expense
-
-
-
-
Net interest expenses
1,34 მლნ.
1,35 მლნ.
1,43 მლნ.
1,36 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-47,80 მლნ.
-40,98 მლნ.
-41,92 მლნ.
-54,79 მლნ.
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google აპები